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6-year clinical results using the ReCap hip
resurfacing system
Walter van der Weegen1*, Henk J Hoekstra1, Thea Sijbesma1, Shennah Austen1 and Rudolf W Poolman2Abstract
Background: The purpose of our study was to prospectively report the clinical results of 280 consecutive hips
(240 patients) who received a ReCap Hip Resurfacing System implant (Biomet Inc., Warsaw, USA) in a single district
general hospital. Literature reports a large variation in clinical results between different resurfacing designs and
published results using this particular design are scarce.
Methods: Mean follow up was 3.3 years (1.0 to 6.3) and four patients were lost to follow-up. All patients were
diagnosed with end-stage hip osteoarthritis, their mean age was 54 years and 76.4% of all patients were male.
Results: There were 16 revisions and four patients reported a Harris Hip Score <70 points at their latest follow up.
There were no pending revisions. Kaplan-Meier implant survival probability, with revision for any reason as
endpoint, was 93.5% at six years follow-up (95%-CI: 88.8-95.3). There were no revisions for Adverse Reactions to
Metal Debris (ARMD) and no indications of ARMD in symptomatic non-revised patients, although diagnostics were
limited to ultrasound scans.
Conclusions: This independent series confirms that hip resurfacing is a demanding procedure, and that implant
survival of the ReCap hip resurfacing system is on a critical level in our series. In non-revised patients, reported
outcomes are generally excellent.
Trial registration: ClinicalTrials.gov Identifier: NCT00603395
Keywords: Hip resurfacing, Implant survival, Adverse reaction to metal debris, ReCap designBackground
Hip resurfacing arthroplasty (HRA) has been widely
used in recent years. Possible advantages of conserved
femoral bone stock, low wear rates and low dislocation
rates were the main reasons for surgeons to use HRA.
Recent concerns on the use of Metal-on-Metal (MoM)
bearings have intensified the discussion on HRA. The
reported increase of metal ion levels after HRA with
subsequent local Adverse Reactions to Metal Debris
(ARMD) and poor results with revision for this compli-
cation have diminished the support for HRA [1-4].
In the published literature there is a wide range of clinical
results between different HRA designs [3,5,6]. Although* Correspondence: kog@st-anna.nl
1Department of Orthopaedic Surgery, St. Anna Hospital, Bogardeind
2Geldrop, EH 5664, Netherlands
Full list of author information is available at the end of the article
© 2012 van der Weegen et al.; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumnumeral clinical studies report short- and mid-term
survival of different HRA systems, these studies focus on a
limited number of HRA designs. To our knowledge, there
are four studies published using the ReCap Hip Resurfacing
System (Biomet Inc., Warsaw, USA). Gagala reported there
were no significant complications after a maximum follow
up (FU) of 20 months, using this implant design (n = 23)
[7]. Baad-Hansen reported no significant translation or
rotation using this implant design (n = 25), after two year
FU using radiostereometry (RSA) [8]. A larger number of
ReCap procedures (n = 137) with a three year FU are
described in the Australian National Joint Replacement
Registry. In this report a cumulative percent revision rate of
7.6% is presented for this specific HRA design [9]. Recently,
Gross and Liu presented the mid-term results of 740 hip
resurfacings with a 3.4% revision rate [10].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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280 consecutive HRA’s using the ReCap Hip Resurfacing
system, with a maximum FU of six years (range: 1–6). We
hypothesised that implant survival would be compliant with
the National Institute for Health and Clinical Excellence
(NICE) benchmark (a revision rate of 10% or less at ten
years, or consistent survival if only shorter FU is available)
[11]. We further hypothesised that the risk for revision in
subgroups based on gender, age and component size is
comparable to findings in published literature.Methods
Patients
Between September 2004 and September 2010 our first
280 consecutive, non-selected HRA procedures (240
patients) in a general district hospital were included in a
prospective cohort study (Table 1).
Patients diagnosed with end stage osteoarthritis (OA)
were indicated for HRA. The entire group involved 240
patients (280 resurfacings) with a mean follow-up of
3.3 years (1 to 6.3) of whom 45 were followed-up for five
years and 30 for six years.
Prior to surgery, a dual energy X-ray absorptiometry
(DEXA) scan was made of all female patients and in all
male patients suspected of osteoporosis. When T and Z
values were below normal, patients were excluded from
HRA. After informing the patient on the expected bene-
fits and risks associated with HRA, informed consent on
the surgery procedure and on study participations was
obtained from all patients. Our study was approved by
the Institutional Review Board. Patients with renal fail-
ure, femoral cysts, osteoporosis or a-vascular necrosis
(AVN) of the femoral head were excluded. Female
patients with a possible child wish were also excluded.Table 1 Demographics of the study group
Mean Range
Age at surgery (yr) 54 28 to 76
BMI 26.5 19 to 46
Hospital stay (days) 3.5 2 to 9
Follow up (months) 39 12 to 75
Count %
Sex (n = 240 patients)
Males 187 77.9
Females 53 22.1
Diagnosis (n = 280 hips)
Primary OA 258 92.1
DDH 19 6.8
Posttraumatic OA 3 1.1
OA indicates osteoarthritis; DDH, developmental dysplasia.Surgical technique and rehabilitation
Two experienced joint arthroplasty surgeons (HJH, TS)
used the ReCap Hip Resurfacing System (Biomet Inc,
Warsaw, USA) in all patients in a standard manner.
Prophylactic antibiotics were administered on induction.
Both the press-fit acetabular component and the cemen-
ted femoral component are manufactured from “as-cast”
cobalt chrome (Co-Cr-Mo) with a high carbon content
(>0.2%). The acetabular outside is a full-hemisphere
design and has four pairs of fins for initial rotational
stability. It has a titanium porous plasma spray surface
coating (Figure 1). The outer geometry of the cemented
femoral component extends approximately 23 degrees
beyond a full-hemisphere. The critical inner bearing sur-
face has a coverage arc ranging from 155–164 degrees
from smallest to largest component.
The posterolateral approach was used in all procedures.
After dislocating the hip joint, acetabular osteophytes were
removed, the acetabulum was reamed and the acetabular
component was impacted into the anatomical position.
Next, a femoral guide wire was inserted into the femoral
head, directed with a jig. The femoral head was then
circumferentially reamed and the bone-bed was prepared
with drill holes and pulse lavage for cementing. After
applying high viscosity cement (RefobacinW Bone Cement
R, Biomet Europe, Dordrecht, Netherlands) to the inner
surface, the femoral component was carefully put in place.
Patients were mobilised the first post-operative day
using two crutches and weight bearing as tolerated.Figure 1 ReCap resurfacing device.
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and the wound was without problems. Physiotherapy was
prescribed to all patients. Patients were instructed to avoid
all high impact activities in the first six months and dis-
couraged to participate in high impact sports. All bilateral
procedures were staged interventions with at least a three
months interval.
Study protocol
Patients were recruited at the time of surgery and
prospectively followed six weeks after surgery and yearly
thereafter. Bilateral cases were followed up as separate
cases. Standard antero-posterior (AP) and lateral radio-
graphs, and the Harris Hip Score [12] were collected at
each visit, except for the six week FU. Only radiographs
were collected at this visit. Any patient who was symptom-
atic post-operatively was analysed with a diagnostic ultra-
sound scan to check for ARMD.
On the plain anterio-posterior (AP) radiograph, the
acetabular angle of inclination and femoral stem shaft
angle were measured as described by Beaulé et al. [13].
Radiolucensies were measured in millimeters and acetabu-
lar radiolucency was classified in three zones according to
DeLee and Charnley (Figure 2A) [14]. Any femoral
radiolucencies were classified in the three zones as
described by Beaulé et al. (Figure 2B) [13]. Heterotopic
bone formation was classified as described by Brooker
et al. [15]. Neck narrowing was measured as described by
Grammatopoulos et al., using the first post operative
radiograph and the most recent radiograph for compari-
son [16]. Clinical and radiological FU and statistical
analyses were done by an independent observer, with a
sample set of radiographic measurements audited by an
experienced radiologist.
Statistical analysis
Revision for any reason was the primary endpoint of this
study. Kaplan-Meier survivorship curves were calculated.Figure 2 A: Acetabular radiolucency zones according to DeLee and CSince we support the recent notion in literature that
implant survivorship is a limited endpoint to define a
successful outcome for joint arthroplasty [17], a HHS
score of < 70 points on the latest FU (two years or more)
was also used as an endpoint for implant failure. The
NICE benchmark (a revision rate of 10% or less at
ten years, or consistent survival if only shorter FU is
available) was used to evaluate survivorship [11].
Relative risks (RR) were calculated to evaluate sub-
group results based on gender, age, component size
and acetabular inclination angle. A femoral head size
< 50 mm and an acetabular inclination angle of ≥ 550
were considered to be a risk factor for ARMD and
therefore revision. [18-20] SPSS software (SPSS Statis-
tics, version 17.0, IBM Corporation, Somers USA)
was used for all statistical analyses. The occurrence of
femoral neck narrowing as a consequence to head
downsizing can also be indicative for ARMD, as
described by Grammatopoulos et al. [16]. Neck nar-
rowing values were calculated as a percentage and
ranges were presented for the whole cohort and for
the patients who were revised > 6 months after index
surgery.
Results
Four patients were deceased for reasons not related
to the HRA procedure (four prostheses, 1.4%) and no
other patient was lost to FU. Three patients were
contacted by phone since they were unable to return
for FU. Therefore, radiological FU was complete for
277 patients. There were 16 revisions at the time of
final FU. Seven were for fracture of the femoral neck,
five for aseptic loosening of the acetabular compo-
nent, two for component malpositioning (one femoral
and one acetabular) and two for persistent pain
(Table 2).
The Kaplan-Meier implant survival probability with
revision for any reason as endpoint was 93.5% at six yearsharnley [14]. B: Femoral radiolucency zones according to Beaulé [13].
Table 2 Revision details
Failure mode Gender Age Fem.comp. Months to revision Revision details
FN# Male 61 48 mm 0.5 Femoral revision
FN# Female 55 46 mm 0.5 Femoral revision
FN# Male 57 52 mm 1 Femoral revision
FN# Male 57 50 mm 1 Femoral revision
FN# Male 60 52 mm 1 Femoral revision
FN# Male 54 50 mm 2 Femoral revision
FN# Male 48 48 mm 18 Femoral revision
Mal Fem Comp Male 60 52 mm 0 Both comp. revised
Mal Acet Comp Male 67 50 mm 12 THP other hospital
Asep Loosening Male 58 54 mm 1 Both comp.revised
Asep Loosening Male 64 50 mm 23 Both comp. revised
Asep Loosening Female 49 44 mm 32 Both comp.revised
Asep Loosening Male 28 50 mm 43 Both comp.revised
Asep Loosening Female 49 42 mm 56 Both comp.revised
Persistent pain Male 43 50 mm 7 THP other hospital
Persistent pain Female 52 50 mm 27 Both comp.revised
FN# indicates fracture of the femoral neck; Mal Fem Comp: malpositioned femoral component; Mal Acet Com: malpositioned acetabular component; Asep Loosening:
Aseptic loosening; Fem comp: femoral component size.
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mean time to revision was 14 months (range: 0 – 56) with
eight out of 16 revisions within two months from index
surgery. Female patients had a RR for revision of 1.1
compared to male patients (95%-CI: 0.92-1.06). The RRFigure 3 ReCap Kaplan-Meier implant survival probability.for revision in the group of patients with a femoral head
<50 mm, was 1.1 compared to the group of patients with
larger components (95%-CI: 0.98-1.09). In the patients
younger 55 years the RR for revision was 0.9 compared to
patients 55 years or older (95%-CI: 0.95-1.07).
Table 3 Kaplan-Meier survival probability data details
Year Number of atstart Failures Withdrawn Number of risk Accumulated survival (%) 95% Confidence interval
0 to 1 280 9 3 279.9 96.4 93.8 to 98.4
1 to 2 259 3 24 257.0 95.7 92.4 to 97.6
2 to 3 229 2 40 222.0 94.8 91.4 to 97.0
3 to 4 185 1 48 176.0 94.3 90.7 to 96.6
4 to 5 135 1 53 124.5 93.5 89.9 to 96.1
5 to 6 80 0 43 75.5 98.5 89.9 to 96.1
6 to 7 37 0 29 29.5 93.5 88.8 to 95.3
Table 4 Complications without need for revision
Complication N (%)
Nerve damage 2 (0.7%)
Non-displaced femoral neck fracture 2 (0.7%)
Deep wound infection 1 (0.4%)
Superficial wound infection 7 (2.5%)
Post-operative bleeding 18 (6.4%)
Total 30 (10.7%)
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In all seven femoral neck fracture cases, the acetabular
shell was left in situ and a stemmed, uncemented femoral
prosthesis was inserted. Six out of seven neck fractures
occurred within two months of the index surgery, one case
was a late neck fracture 18 months post-operatively.
During revision surgery of this one case it was observed
that the femoral component was loose, which was thought
to be caused by avascular necrosis of the femoral head. In
all other cases both components were replaced. All cases
of aseptic loosening only involved the uncemented acetab-
ular component. Of the none-revised patients, there were
four patients with a HHS score < 70 points at their latest
FU (two at two years and two at three years FU). Revision
and clinical score combined as endpoint for implant fail-
ure, resulted in 20 failed prostheses at the time of final FU.
During revision surgery no metallosis, soft tissue cysts or
solid masses were observed, although postoperative histo-
pathological analyses showed chronic inflammatory signs
including synovial hyperplasia en some metallosis in both
patients revised for persistent pain, indicating adverse local
tissue reaction to metal debris. A diagnostic ultrasound
was made in 27 patients (9.6%) with unexplained hip or
groin pains, all were normal. In our series there were 81
patients with an acetabular inclination angle of 55°-65° (of
which 23 had a femoral head size <50 mm) and 10 patients
with an acetabular inclination angle of >65° (of which four
had a femoral head size <50 mm). In none of these patients
any signs of ARMD were observed during any revision
surgery or additional diagnostic ultrasound scans.
Complications without need for revision
There were 30 (10.7%) complications without need for
revision (Table 4).
The majority of these complications were transient
such as post operative bleeding (n = 18). There was one
deep wound infection which was eradicated after surgi-
cal debridement and antibiotic treatment. Seven other
patients with signs of a post-operative wound infection
were treated successfully with antibiotics. There was one
patient with persistent paraesthesia and pareses of the
foot due to an sciatic nerve lesion. One other patient
had a transient nerve palsy of the sciatic nerve. Anotherpatient was treated conservatively for a non-displaced
fracture of the femoral neck, which he sustained due to
a fall three months after surgery. He recovered without
any persistent symptoms. A healed non-displaced fem-
oral neck stress fracture was discovered with routine FU
two years post-operatively (Figure 4A and 4B). This
patient had experienced some groin pain after running,
which completely resolved when he did not run for a
couple of weeks. There were no dislocations or thrombo-
embolic events in our series.Outcomes
At one year FU, mean HHS had improved significantly
from pre-operative scores (from 49.3 to 92, p < 0.0001,
Table 5).
At six year FU, 36 patients had an “excellent” HHS
(66.7%), 16 a “good” HHS (29.6%) and two a “fair” HHS
(3.7%). For the revised patients, the mean HHS after
revision was 77 (range 41–91).Radiological findings
At one year FU, the mean implant femoral shaft angle
was 135.10 (range 1160-1560). Mean acetabular angle of
inclination was 51.30 (range: 260 – 770). With further
FU, no radiolucensies were observed. Ectopic bone
formation was noted in 13.8% of all cases. Mean HHS
for patients who had a Brooker grade two or three
ectopic bone formation was 91 points (range: 74–91)
(Table 5). Neck narrowing was observed in 136 patients
with a mean of 2.3% (range: 0%-18.5%). In the patients
with revisions later than 6 months after index surgery,
neck narrowing was present in 3 out of 9 patients. One
Figure 4 A: Non-displaced partial femoral neck fracture. B:
Healed femoral neck fracture.
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neck narrowing.
Discussion
Our KM-survival probability of 93.5% at six years FU
(95%-CI: 88.8-95.3) is not compliant with the three year
entry NICE benchmark. Longer FU is needed to
compare our results with the full 10-year benchmark. Of
the non-revised patients, there were only four patients
with implant failure based on their HHS score. The
combined endpoints of revision (n = 16) and HHS score
< 70 points (n = 4), resulted in 20 failed prosthesis
(7.1%). Since no other studies on MoM hip resurfacingTable 5 Clinical and radiographic findings
HHS Fem. Pos.
Pre op (n = 280) 49.3 n/a
6 wks (n = 280) - +2.20
1 yr (n = 280) 92 -
2 yrs (n = 221) 88.3 -
6 yrs (n = 54) 89.3 -
HHS indicates mean Harris Hip Score; Fem. Pos, mean varus/valgus placement compar
mean cup abduction angle; Br. 1/2/3/4, Ectopic Bone Formation classified as Brooker ghave combined implant survival and Patient Reported
Outcome scores to define implant performance, we
cannot compare this result to other studies. We were
able to identify all failure modes, including those from
patients revised in other hospitals. Most frequent
reasons for revision were fracture of the femoral neck
(n = 7) and aseptic loosening (n = 5). All cases of aseptic
loosening occurred relatively early and involved only the
uncemented acetabular component. We think that insuf-
ficient seating of the acetabular component, which might
occur due to deformation of the relatively thin cup
during the impaction procedure, may have caused these
early revision cases. In our series we have not observed
any signs of ARMD during revision surgery, although
post revision surgery two patients revised for persistent
pain had histopathological evidence of adverse local
tissue reaction (ALTR) to metal debris. Neither have we
observed any signs of ARMD with diagnostic ultrasound
scans in patients who were post-operatively symptom-
atic. We cannot completely rule out the presence of
ARMD in our series, but since we observed two cases of
ALTR, future follow-up will include routine metal ion
analysis. Our complete FU, our detailed information on
revision cases and the excellent clinical scores at the
time of final FU are in contrast to other designs of HRA,
of which failure rates of 25% for ARMD after six years
FU are reported [21]. Risk factors for ARMD are the
inclination angle of the acetabular cup, implant design,
small component sizes and occurrence of neck narrow-
ing. Steep inclination angles and an acetabular cup with
less than hemispherical coverage result in a small
contact patch area (CPA), which increases the wear rate.
Another risk factor is component size, with small sizes
resulting in more friction, releasing more metal debris
[18-20]. In our series there were 81 patients with such
risk factors, but no ARMD was observed in any of these
patients, neither with a diagnostic ultrasound scan nor
during revision surgery. The critical inner bearing
surface of the ReCap has a coverage arc ranging from
155–164 degrees from smallest to largest component
which is similar to other designs with a larger CPA such
as the Birmingham Hip Resurfacing design (Smith and
Nephew PLC, London, UK), the Conserve plus (Wright
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Our findings on ARMD are in line with several other
studies. Malviya found a 0.15% incidence of pseudotumors
using the Birmingham Hip Resurfacing (BHR) [22]. Beaulé
et al. found a 0.1% prevalence of pseudotumors with MoM
resurfacing after surveying nine Canadian Academic cen-
ters [23]. Glyn-Jones et al. extensively studied the risk
factors for pseudotumor formation in a large series of hip
resurfacings. Gender and age had a significant independent
influence on the revision rate for pseudotumour formation,
and the incidence increased with time, with a mean time
to pseudotumour revision of 3.5 years (1 to 8.3 years) [24].
In the series presented by Steffen et al., there were three
revision cases possibly related to metal debris. Two of
these cases were revised around two years post-operatively,
the other one at 5.6 years after surgery [25]. These mean
times to pseudotumour revision are within the maximum
follow-up time of our case series (6.3 years), but we will
have to stay alert on ARMD occurrence with longer
follow-up.
Grammatopoulos reported a mean 10.1% neck nar-
rowing in patients revised for pseudotumours. In our
cohort the mean percentage of neck narrowing was
considerably lower (2.3%), although individual cases had
greater neck narrowing. We did observe neck narrowing
in three out of the nine patients who were revised >
6 months after index surgery, but these three patients
had less than 10% neck narrowing. Neck narrowing data
from our cohort is supplementary to the observations by
Gross and Liu. They also report < 1% revisions for
adverse wear and based on their report and on data from
our cohort we believe that the risk for adverse wear
using this resurfacing design is low. Gross did report a
lower revision rate compared to our study (3.4% versus
7.3%) but in his series the learning curve was avoided
since the surgeon had performed 400 hip resurfacings
before the presented series was started [10]. As noted in
the study by Gross, we also now have begun recom-
mending routine metal ion tests in all our patients.
Strong points of our study are its prospective study
design, a large consecutive study cohort, limited lost to
FU and comparison to an objective benchmark. There is
detailed FU on all revised patients including those
revised in other hospitals, and both clinical outcome
scores and radiological FU were analysed. Another
advantage is that this study was conducted in a general
district hospital rather than a design institution. Our
study also has limitations: FU time is limited and there
is no control group. We also have to bear in mind that
the NICE-benchmark is applied to an OA population of
all ages, and literature describes higher revision rates in
younger patients [26-28]. Metal-ion levels were not
obtained and there were no diagnostic ultrasounds made to
check for ARMD in non-symptomatic patients. Comparedto published literature, our study reports the clinical results
on more patients with longer FU using the ReCap Hip
Resurfacing system than any other study. Gagala et al.
studied 25 patients (mean FU 11 months, range: 10–20)
and found good short-term clinical results without signifi-
cant complications [7]. Baad-Hansen et al. conducted a
radiostereometric analysis (n = 23). There was no statisti-
cally significant translation or rotation of the femoral
component observed after two years FU [8]. The absence
of any revisions in these series might be due to the small
number of patients and the short FU. In the evaluation of
risk factors for early failure with HRA, the Australian
Arthroplasty Register reported on 137 procedures between
1999 and 2008 using the ReCap hip resurfacing system [9].
Their cumulative percent revision rate of 7.6% at three year
FU using this system was worse than our implant survival
at three years. A possible explanation might be that those
137 procedures were done by a large number of orthopedic
surgeons in an extended period of time, limiting the
individual expertise using this system. However, despite
further enquiry, no more details could be provided by the
Australian Arthroplasty Register.
Regarding patient selection, in our series the RR for
revision was slightly higher for female and for older
patients, although statistically the difference was not
significant. Patients with smaller component sizes had a
higher risk for revision, but this was also not statistically
significant. This is in line with several other publications
which show a significantly higher risk for revision in
female patients, older patients, and in patients with
small components [5,29-32]. The possible absence of
ARMD in our series might explain the equal risk for
revision in patients with small or large component sizes.
Looking at diagnosis, literature reports that the best
HRA results are obtained with OA [5,33]. In our series,
only patients with this diagnosis were included.
Conclusion
Although implant survival rate in our series is below the
NICE benchmark, patient reported outcomes are excel-
lent in the non-revised patients. Also, we were not able
to detect signs of ARMD with standard radiographs and
clinical outcome scores. As with other resurfacing
designs, this resurfacing system should be regarded as a
difficult but effective surgical procedure for a small and
specific patient population.
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